Condensed consolidated statement of income

IFRS 16 “Leases” was adopted per January 1, 2019, applying the modified retrospective method. In the Statement of income for the first half-year of 2019, the Operating lease expenses (€54 million), previously recorded in operating income, are replaced by the depreciation charge on Right-of-use assets (€51 million; remains recorded in operating income) and by Interest expenses for the lease liability (€3 million; recorded in Net financing expenses). The 2018 comparative figures have not been restated.

On a net basis, the adoption of IFRS 16 has led to an increase of operating income by €3 million and an increase of Net financing expenses by €3 million; Profit before tax and profit for the period remained unchanged.

The Specialty Chemicals business is reported as discontinued operations. Therefore, the results of the Specialty Chemicals business are included on the line “Profit for the period from discontinued operations” in the Condensed consolidated statement of income.

Condensed consolidated statement of income

Second quarter

 

January-June

2018

2019

in € millions

2018

2019

Continuing operations

2,446

2,451

Revenue

4,622

4,636

(1,390)

(1,375)

Cost of sales

(2,646)

(2,655)

1,056

1,076

Gross profit

1,976

1,981

(864)

(765)

SG&A costs

(1,676)

(1,556)

(3)

Other results

(4)

192

308

Operating income

300

421

(28)

(18)

Net financing expenses

(9)

(31)

6

5

Results from associates and joint ventures

10

10

170

295

Profit before tax

301

400

(47)

(69)

Income tax

(46)

(100)

123

226

Profit for the period from continuing operations

255

300

 

 

 

 

 

Discontinued operations

165

16

Profit for the period from discontinued operations

307

16

288

242

Profit for the period

562

316

 

 

 

 

 

Attributable to

271

231

Shareholders of the company

524

296

17

11

Non-controlling interests

38

20

288

242

Profit for the period

562

316